Nano cap Hepion Pharmaceuticals (NASDAQ:HEPA) announces positive results on lead drug CRV431 in two preclinical research models related to COVID-19.
CRV431, a cyclophilin inhibitor, showed anti-inflammatory effects in a non-viral acute lung injury model, outperforming dexamethasone in some measures. It also showed antiviral activity against SARS-CoV-2 in cell culture experiments.
Additional preclinical testing is next up.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.